Myeloma mesenchymal stem cells’ bioenergetics afford a novel selective therapeutic target
Oded Komemi(Tel Aviv University), Liat Drucker(Meir Medical Center), Metsada Pasmanik‐Chor, Osnat Jarchowsky-Dolberg(Tel Aviv University), Yaron S. Brin(Meir Medical Center), Shelly Tartakover‐Matalon(PharmacoGenetics (China)), Michael Lishner(Tel Aviv University), Elina Orbuch(Tel Aviv University)
Cited by 4
Related Papers
High incidence of BRCA1–2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma
|European Journal of Surgical Oncology|2006|63
Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential
|The FASEB Journal|2007|56
Simvastatin has deleterious effects on human first trimester placental explants
|Human Reproduction|2005|51
Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation
|Tumor Biology|2015|48
BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma
|International Journal of Gynecological Cancer|2010|47